Jacob-Dolan 2023 determined determine immune correlations of protection in rhesus macaques following administration of a broadly protective SARS-CoV-2 vaccine and subsequent SARS-CoV-2 challenge, through comparisons of humoral responses and viral load.
Milestone
2.6.f
Animal models for CoPs
In progress
Conduct studies in animal models to identify CoPs for evaluating broadly protective coronavirus vaccines.
Progress Highlights
C57BL/6 mice have been used to demonstrate a cross-reactive mucosal IgA response to multiple SARS-CoV-2 variants following intranasal vaccination with a lipopeptide-based vaccine candidate.
- Patel 2025: Mixed lipopeptide-based mucosal vaccine elicits a long-term bone marrow memory response that is potentially cross-reactive against a broad-spectrum of coronaviruses in mice
- Patel 2023: Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune responses in mice
Hsu 2025, in a similar study in hamsters using intranasal measles virus- and mumps virus-based SARS-CoV-2 vaccine candidates, showed the induction of broad NAbs, mucosal IgA and lung TRM, providing complete protection against multiple SARS-CoV-2 variants despite WA1 imprinting, and trivalent blockade of WA1/XBB.1.5 transmission
Yuen 2023 used K18-hACE2 transgenic mice to demonstrate protection against lethal SARS-CoV-2 challenge following intranasal administration of a pan-sarbecovirus vaccine; all mice that received the vaccine survived challenge, and had anti-RBD and anti-N IgG titers ≥104, and FRNT50 and FRNT75 titers ≥102 28 days post-vaccination; antigen-specific CD4+ and CD8+ T-cell activation was also demonstrated in bronchoalveolar lavage and dissociated lung samples.